AlphaVax, Inc. company was founded in 1998 by Robert Johnston, Nancy Davis, and Jonathan Smith, AlphaVax's chief scientific officer. AlphaVax, Inc. company is developing new vaccines for cancers and infectious diseases such as HIV/AIDS, Ebola, influenza, and other viral maladies. AlphaVax relies on a proprietary alphavaccine system that genetically alters diseased cells and transforms them into a vaccine when they attempt to replicate. Its technology could be used to develop preventative vaccines and therapeutic vaccines. Its pipeline consists of early-stage candidates. AlphaVax receives funding through partnerships and grants.

Morphotek has mighty morphin' power, but don't expect to find its products on the shelves of the local toy store. The biotechnology company develops monoclonal antibody (single-source protein) therapies for the treatment of cancer, inflammation, and infectious diseases using its proprietary Morphogenics technology platform. It conducts research and clinical development programs on its own drug candidates for ailments such as ovarian and pancreatic cancers, rheumatoid arthritis, and asthma. Morphotek also enters collaborative research partnerships and licenses out its technology to other drug companies such as Amgen and Novo Nordisk. The company is a subsidiary of Eisai Inc., part of Japanese drug firm Eisai.

Kendle International Inc. was founded in 1981 and is based in Cincinnati, Ohio. Kendle International Inc. is a global clinical research organization (CRO) that provides a range of Phase I-IV global clinical development services to the biopharmaceutical industry. The Company augments the research and development activities of biopharmaceutical companies by offering clinical research services and information technology designed to reduce drug development time and expense. Kendle International Inc. is managed in two reportable segments: Early Stage and Late Stage. The Early Stage business focuses on the Company’s Phase I operations while Late Stage is comprised of clinical development services related to Phase II through III clinical trials conducted worldwide, late phase clinical development services related to Phase IIIB and IV clinical trials conducted worldwide, regulatory affairs and biometrics offerings. In June 2008, the Company announced the acquisition of DecisionLine Clinical Research Corporation.

ChemOvation offers contract drug discovery research and design services to pharmaceutical and biotechnology companies. ChemOvation has expertise in organic and medicinal chemistry, and drug discovery. ChemOvation also provides protein binding and compound solubility measurements for clients' metabolism research. ChemOvation's team of contractors is built around a core of organic chemists and technicians. Formed in 1999, the company merged with KuDOS Pharmaceuticals in 2000. ChemOvation dissolved those bonds in 2005 having spun off from KuDOS and is independent once again.

Opko Health Inc. is a specialty healthcare company. The Company is focused on the discovery, development and commercialization of pharmaceuticals, drug delivery technologies, diagnostic systems, and instruments for the treatment, diagnosis and management of ophthalmic diseases and conditions. Its business consists of the development of ophthalmic pharmaceuticals and the development, commercialization and sale of ophthalmic diagnostic and imaging systems and instrumentation products. It focuses on exploring opportunities to acquire complementary pharmaceuticals, compounds, and technologies, which could, individually or in the aggregate, materially increase the scale of the Company’s business. On May 6, 2008, the Company completed the acquisition of Vidus Ocular, Inc. (Vidus).

Nanospectra Biosciences, Inc. was founded in 2002 and is based in Houston, Texas. Nanospectra Biosciences, Inc., a medical device company, engages in developing and commercializing particle-based therapies for the selective and precise thermal destruction of solid tumors. The company provides AuroLase Therapy, a medical device that is applicable to the ablation of various solid tumors. It also offers research-use-only nanoparticles with specific optical characteristics.

Protein Polymer Technologies, Inc. company was founded in 1988 and is based in San Diego, California. Protein Polymer Technologies, Inc., a biotechnology company, engages in the research, development, and production of bio-active devices to improve medical and surgical outcomes. The company, through its proprietary technology, produces molecular weight polymers that can be processed into a range of material forms, such as gels, sponges, films, and fibers. It also focuses on developing protein polymers that are used in products for tissue augmentation, tissue adhesives and sealants, and drug delivery devices. The company also develops and offers surgical tissue sealants that include tissue adhesives and sealants; wound healing and tissue regeneration products, including fabric dressings, synthetic materials, and biological materials; and urethral bulking agent that relieves female stress incontinence. In addition, it develops coating technology that modifies and improves surface properties of traditional biomedical devices.

MannKind Corporation was founded in 1991 and is headquartered in Valencia, California. MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diseases, such as diabetes and cancer. Its lead product candidate, AFRESA, a rapid-acting insulin that has completed phase 3 clinical trials for the treatment of diabetes in the United States, Europe, and Japan. The company's lead product candidates also include MKC1106-PP, which is in phase I clinical trial for the treatment of various solid-tumor cancers, including ovarian, colorectal, pancreatic, renal, breast, non-small cell lung and prostate carcinomas, glioblastoma, and melanoma.

Viventia Biotechnologies Inc., a biopharmaceutical company, offers a portfolio of novel antibody-based drugs for the treatment of cancer. Its lead product, Proxinium is used for the treatment of head and neck cancer. The company also offers Vicinium, a product for the treatment of bladder cancer; and VB6-845, a product for the treatment of solid tumors. Viventia specializes in the discovery and development of a portfolio of monoclonal antibodies for the treatment of common cancers. It also has a location in Winnipeg, Canada. The company was formerly known as Novopharm Biotech, Inc. and changed its name to Viventia Biotech, Inc. in 2000. The company was is headquartered in Mississauga, Canada. As of December 28, 2005, Viventia Biotechnologies Inc. operates as a subsidiary of Dan Family Holdings, Ltd.

RXi Pharmaceuticals was founded in 2003 and is based in Worcester, Massachusetts. RXi Pharmaceuticals Corporation, a discovery-stage biopharmaceutical company, focuses on the development and commercialization of proprietary therapeutics based on RNA interference for the treatment of human diseases in the United States and internationally. It intends to identify lead compounds and advance towards pre-clinical and clinical development programs in various therapeutic areas, including inflammatory disease; and metabolic diseases, such as obesity and obesity-related type 2 diabetes. The company was formerly known as Argonaut Pharmaceuticals, Inc. and changed its name to RXi Pharmaceuticals Corporation in 2006 before beginning operations in 2007.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.